Novel insights into anti-CD40/CD154 immunotherapy in transplant tolerance

David F. Pinelli*, Mandy L. Ford

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

32 Scopus citations

Abstract

Since the discovery of the CD40-CD154 costimulatory pathway and its critical role in the adaptive immune response, there has been considerable interest in therapeutically targeting this interaction with monoclonal antibodies in transplantation. Unfortunately, initial promise in animal models gave way to disappointment in clinical trials following a number of thromboembolic complications. However, recent mechanistic studies have identified the mechanism of these adverse events, as well as detailed a myriad of interactions between CD40 and CD154 on a wide variety of immune cell types and the critical role of this pathway in generating both humoral and cell-mediated alloreactive responses. This has led to resurgence in interest and the potential resurrection of anti-CD154 and anti-CD40 antibodies as clinically viable therapeutic options.

Original languageEnglish (US)
Pages (from-to)399-410
Number of pages12
JournalImmunotherapy
Volume7
Issue number4
DOIs
StatePublished - Apr 1 2015

Keywords

  • CD40
  • CD40L
  • Fc receptor
  • costimulation
  • thromboembolism
  • transplantation

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Fingerprint Dive into the research topics of 'Novel insights into anti-CD40/CD154 immunotherapy in transplant tolerance'. Together they form a unique fingerprint.

Cite this